Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
The first chlamydia vaccine to reach Phase I clinical trials has been observed to be safe and immunogenic in 35 women.
In a study of healthy infants, researchers discover exposure to C. difficile in infancy may provide natural immunization later in childhood.
Researchers from the University of Texas at Austin have passed an experimental RSV vaccine through Phase I human clinical trial with promising results.
The outbreak of Ebola in the Democratic Republic of Congo has seen over 2612 cases and 1756 mortalities since it was first announced by the WHO on 1 August 2018. One year on we ask, what have the major milestones been of this outbreak? And where are we now; is there an end in sight?
Research suggests that in the UK, new cases of tick-borne Lyme disease could be three-times higher than previous estimates, possibly exceeding 8000 cases in 2019.
Take a look at this month’s industry headlines including a US FDA approval for RECARBRIO™, positive results for XOFLUZA in children and new ACIP recommendations.
A DNA vaccine for MERS-CoV was demonstrated to be well-tolerated and immunogenic in a Phase I, first-in-human trial.
In this interview we speak to Leah Blondeau about her research into the pathogens that can be passed from companion animals to humans, recently presented in a poster at the European Congress of Clinical Microbiology and Infection Disease.
